Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
January 15 2021 - 11:43AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of January 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc (the 'Company')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms E Walmsley
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 14 January 2021, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8719
|
28
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2021-01-14
|
|
f)
|
Place
of the
transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr R Connor
|
|
b)
|
Position/status
|
President, Global Vaccines
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 14 January 2021, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8719
|
84
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2021-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms D Conrad
|
|
b)
|
Position/status
|
SVP, Human Resources
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 14 January 2021, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8719
|
4
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2021-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr J Ford
|
|
b)
|
Position/status
|
SVP & General Counsel
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 14 January 2021, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8719
|
2
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2021-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr N Hirons
|
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 14 January 2021, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8719
|
19
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2021-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms S Jackson
|
|
b)
|
Position/status
|
SVP, Global Communications and CEO Office
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 14 January 2021, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8719
|
77
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2021-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr D Jackson
|
|
b)
|
Position/status
|
PCA of Ms S Jackson (SVP, Global Communications and CEO
Office)
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 14 January 2021, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8719
|
28
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2021-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr L Miels
|
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 14 January 2021, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8719
|
4
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2021-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr D Redfern
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 14 January 2021, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8719
|
94
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2021-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr R Simard
|
|
b)
|
Position/status
|
President, Pharmaceuticals Supply Chain
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 14 January 2021, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8719
|
28
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2021-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr P C Thomson
|
|
b)
|
Position/status
|
President, Global Affairs
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 14 January 2021, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8719
|
56
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2021-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms D Waterhouse
|
|
b)
|
Position/status
|
Chief Executive Officer of ViiV Healthcare
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 14 January 2021, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8719
|
76
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2021-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms V Whyte
|
|
b)
|
Position/status
|
Company Secretary
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 14 January 2021, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.8719
|
69
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2021-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: January
15, 2021
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From Nov 2023 to Nov 2024
